MODIFIED METHODS OF DRUG DELIVERY IN MODERN ONCOLOGY

Download full text PDF
Issue: 
3
Year: 
2017

А. Zaborovsky (1), Candidate of Medical Sciences; Professor K. Gurevich (1), MD; Professor E. Lobanova (1), MD; I. Krysanov (2), Candidate of Pharmaceutical Sciences; L. Tararina (1); D. Yunina (1) 1-A.I. Evdokimov Moscow State University of Medicine and Dentistry 2-Institute of Socomedical Technologies, Moscow

The paper considers new directions in the medical treatment of neoplasms. Special attention is paid to the targeted transport of drugs through various carriers as the most promising area of chemotherapy.
Keywords: 
oncology
chemotherapy
targeted transport
drug carriers

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Fitzmaurice C., Allen C., Barber R. et al. Global Burden of Disease Cancer Collaboration // JAMA Oncol. – 2016; doi: 10.1001/jamaoncol.2016.5688.
  2. Cronin P., Kirkbride B., Bang A. et al. Long-term health care costs for patients with prostate cancer: A population-wide longitudinal study in New South Wales, Australia // Asia Pac. J. Clin. Oncol. – 2016; doi: 10.1111/ajco.12582.
  3. Jones J., Olson K., Catton P. et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors // J. Cancer Surviv. – 2016; 10 (1): 51–61. doi: 10.1007/s11764-015-0450-2
  4. Chissov V.I. Onkologija. Nats. rukovodstvo / M.: GEOTAR-Media, 2008; 1060 s.
  5. Hvastunov R.A., Skrypnikova G.V., Usachev A.A. Targetnaja terapija v onkologii // Lekarstv. vestnik. – 2014; 8 (56): 3–10.
  6. Jurkin A.K., Tyrenko V.V., Maksimov A.G. i dr. Sravnitel'naja harakteristika pokazatelej krovi v dinamike lechenija bol'nyh zlokachestvennymi limfomami // Vest. Ros. voenno-med. akademii. – 2016; 2 (54): 28–33.
  7. Mandrekar S., Dy G., Furth A. et al. Complementary and alternative medicine (CAM) use by patients enrolled in phase I clinical trials // J. Clin. Oncol. – 2004; 22 (suppl. 14): 8053.
  8. Blunt J., Copp B., Keyzers R. et al. Marine natural products // Nat. Prod. Rep. – 2013; 30 (2): 237–323. doi: 10.1039/c2np20112g. Review.
  9. Ghaly P., Abou El-Magd R., Churchill C. et al. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation // Oncotarget. – 2016; 7 (26): 40518–30. doi: 10.18632/oncotarget.9642.
  10. Lagunin A.A., Druzhilovskij D.S., Rudik A.V. i dr. Vozmozhnosti komp'juternoj otsenki skrytogo potentsiala fitokomponentov lekarstvennyh rastenij iz traditsionnoj indijskoj meditsiny Ajurveda // Biomed. himija. – 2015; 61 (2): 286–97.
  11. Hadjiandreou M., Mitsis G. Mathematical modeling of tumor growth, drug-resistance, toxicity, and optimal therapy design // IEEE Trans Biomed Eng. – 2014; 61 (2): 415–25.
  12. Maurel J., Postigo A. Prognostic and Predictive Biomarkers in Colorectal Cancer. From the Preclinical Setting to Clinical Practice // Curr. Cancer Drug Targets. – 2015; 15 (8): 703–15.
  13. Cheng Y., Zhang A., Hu J. et al. Multifunctional Peptide-Amphiphile End-Capped Mesoporous Silica Nanoparticles for Tumor Targeting Drug Delivery // ACS Appl Mater Interfaces. – 2016; doi: 10.1021/acsami.6b12647.
  14. Rosen L., Gordon M., Bai S. et al. A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors // J. Clin. Oncol. – 2011; 29 (Suppl. 15): 2614.
  15. Treschalin I.D., Pereverzeva E.R., Bodjagin D.A. i dr. Modifikatsija toksichnosti protivoopuholevyh prepararatov kak metod povyshenija effektivnosti himioterapii zlokachestvennyh novoobrazovanij // Ros. bioterapevt. zhurn. – 2005; 4 (3): 87–94.
  16. Kirtane A., Kalscheuer S., Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: shallenges and opportunities // Adv. Drug Deliv. Rev. – 2013; 65 (13–14): 1731–47. doi: 0.1016/j.addr.2013.09.001. Epub 2013 Sep 10.
  17. Gabizon A., Patil Y., La-Beck N. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy // Drug Resist. Updat. – 2016; 29: 90–106. doi: 10.1016/j.drup.2016.10.003.
  18. Krysanov I.S. Farmakoekonomicheskij analiz primenenija liposomal'nogo pegilirovannogo doksorubitsina (Keliks) dlja lechenija metastaticheskogo raka molochnoj zhelezy u bol'nyh s povyshennym riskom kardiologicheskih oslozhnenij // Kachestvennaja klin. praktika. – 2016; 1: 25–32.